{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-032077","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.568478+00:00","generated_at":"2026-05-15T09:41:44.412924+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"confidence":"high","headline":"Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track","bullets":["Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.","Cash and equivalents $109.4M at Dec 31, 2025; Feb 2026 offering raised ~$144M gross.","R&D expenses $42.1M, up 73% YoY, driven by Phase 2 tibulizumab programs.","Phase 2 TibuSHIELD (HS) topline data expected Q4 2026; TibuSURE (SSc) data H1 2027.","Appointed Sandeep Kulkarni as CEO in Jan 2026; added two board members in Feb 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-032077","json":"https://secwatch.observer/filing/0001104659-26-032077.json","markdown":"https://secwatch.observer/filing/0001104659-26-032077.md","text":"https://secwatch.observer/filing/0001104659-26-032077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/0001104659-26-032077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/tm269296d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:41:44.412924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}